Randomized phase 3 trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU) - GRID trial
Author(s):
Reichardt, P.; Demetri, G.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.; Rutkowski, P.; Hohenberger, P.; Gelderblom, H.; Leahy, M.; Mehren, M. von; Schoffski, P.; Blackstein, M.; Cesne, A. le; Badalamenti, G.; Xu, J.; Nishida, T.; Laurent, D.; Kuss, I.; Casali, P.
